

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

**1-10. (cancelled).**

**11. (currently amended):** A composition comprising an antibody or fragment thereof, wherein said antibody or said fragment comprises a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region ~~comprising~~ comprises the amino acid sequence of SEQ ID NO:7, and wherein said light chain variable region comprises three complementarity determining regions having the amino acid sequence of SEQ ID NOs: 4-6; and a therapeutic agent; wherein said antibody or said fragment specifically binds IGF-IR.

**12-13. (cancelled).**

**14. (currently amended):** A composition comprising an antibody or fragment thereof, wherein said antibody or said fragment comprises a heavy chain variable region and a light chain variable region, wherein said light chain variable region ~~comprising~~ comprises the amino acid sequence of SEQ ID NO:8, and wherein said heavy chain variable region comprises three complementarity determining regions having the amino acid sequence of SEQ ID NOs: 1-3; and a therapeutic agent; wherein said antibody or said fragment specifically binds IGR-IR.

15. (currently amended): A composition comprising an antibody or fragment thereof, wherein said antibody or said fragment comprises a heavy chain variable region and a light chain variable region, and wherein said antibody or said fragment specifically binds IGR-IR, wherein said light chain region comprises the~~comprising an~~ amino acid sequence selected from the group consisting of:

SEQ ID NO:9;

SEQ ID NO:10;

SEQ ID NO:11; and

SEQ ID NO:12; and wherein said heavy chain variable region comprises three complementarity determining regions having the amino acid sequence of SEQ ID NO: 1-3; and

wherein said composition further comprises a therapeutic agent.

16. (currently amended): A composition comprising an antibody or fragment thereof, wherein said antibody or said fragment specifically binds IGF-IR, wherein said antibody comprises a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region comprises~~comprising the~~ amino acid sequence of SEQ ID NO:13, and wherein said light chain variable region comprises three complementarity determining regions having the amino acid sequence of SEQ ID NOs: 4-6; and a therapeutic agent.

17. (currently amended): The composition of any one of ~~claims 8~~claims 38, 11 or 14-16, wherein said therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen,

**AMENDMENT UNDER 37 C.F.R. § 1.116**  
**U.S. Application No. 10/729,441 (A8689)**

toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin, rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, erlonitib, anti-EGF receptor antibody, ~~thalidomide, carmustine, prednisone, interferon alpha-2a, vincristine, pamidronate, erythropoietin, bisphosphonate and an~~ epoethilone.

**18. (currently amended):** The composition of any one of ~~claims 38~~claims 8, 11 or 14-16, wherein said therapeutic agent is selected from the group consisting of carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, and camptothecin.

**19-21. (cancelled).**

**22. (currently amended):** The method of ~~any one of claims 19-24~~claim 51, wherein said cancer is a cancer selected from the group consisting of breast cancer, colon cancer, ovarian carcinoma, osteosarcoma, cervical cancer, prostate cancer, lung cancer, synovial carcinoma, pancreatic cancer, melanoma, multiple myeloma, neuroblastoma, and rhabdomyosarcoma.

**23-25. (cancelled).**

AMENDMENT UNDER 37 C.F.R. § 1.116  
U.S. Application No. 10/729,441 (A8689)

26. **(currently amended):** The method of claim ~~24~~51, wherein said cell is contacted with said antibody or said fragment and said therapeutic agent concurrently.
27. **(currently amended):** The method of claim ~~24~~51, wherein said cell is contacted with said antibody or said fragment and said therapeutic agent sequentially and in either order.
28. **(withdrawn-currently amended):** The method of claim ~~25~~52, wherein said antibody or said fragment and said second therapeutic agent are administered concurrently.
29. **(withdrawn-currently amended):** The method of claim ~~25~~52, wherein said antibody or said fragment and said ~~second~~-therapeutic agent are administered sequentially and in either order.
30. **(currently amended):** The method of claim ~~24-51~~ or ~~25~~53, wherein said therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen, toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin, rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, erlonitib, anti-EGF receptor antibody, ~~thalidomide, carmustine,~~

AMENDMENT UNDER 37 C.F.R. § 1.116  
U.S. Application No. 10/729,441 (A8689)

~~prednisone~~, interferon alpha-2a, vincristine, pamidronate, ~~erythropoietin~~, ~~bisphosphonate~~ and an epoethilone.

31. (currently amended): The method of claim ~~24-51~~ or ~~2553~~, wherein said therapeutic agent is selected from the group consisting of carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, and camptothecin.

32. (currently amended): The composition of claim ~~838~~, wherein said therapeutic agent is selected from the group consisting of bortezomib, melphalan, thalidomide, doxorubicin, cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, pamidronate, carmustine, ~~prednisone~~, zoledronate, ~~erythropoietin~~, ~~bisphosphonate~~ and dexamethasone.

33. (currently amended): The composition of any one of claims ~~838~~, 11 or 14-16, wherein said therapeutic agent is selected from the group consisting of bortezomib, melphalan, ~~thalidomide~~, doxorubicin, cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, pamidronate, ~~carmustine~~, ~~prednisone~~, zoledronate, ~~erythropoietin~~, ~~bisphosphonate~~ and dexamethasone.

34. (currently amended): The method of claim ~~24-51~~ or ~~2553~~, wherein said therapeutic agent is selected from the group consisting of bortezomib, melphalan, ~~thalidomide~~, doxorubicin, cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, ~~pamidronate~~, carmustine, ~~prednisone~~, zoledronate, ~~erythropoietin~~, ~~bisphosphonate~~ and dexamethasone.

35. **(withdrawn-currently amended):** The method according to claim 2052, wherein said effective amount of the composition of claim 8-38 comprises about 1 mg/square meter to about 2000 mg/square meter of said antibody or fragment thereof, and about 10 mg/square meter to about 2000 mg/square meter of said therapeutic agent.

36. **(withdrawn-currently amended):** The method according to claim 2052, wherein said effective amount of the composition of claim 8-38 comprises about 10 mg/square meter to about 1000 mg/square meter of said antibody or fragment thereof, and about 50 mg/square meter to about 1000 mg/square meter of said therapeutic agent.

37. **(currently amended):** The composition of claim 838, wherein said antibody or said fragment is selected from the group consisting of:

- (i) a resurfaced antibody or epitope binding fragment thereof;
- (ii) a human antibody or epitope binding fragment thereof;
- (iii) a humanized antibody or epitope binding fragment thereof; and
- (iv) an antibody produced by mouse hybridoma EM164 (ATCC accession number PTA 4457) or epitope binding fragment thereof.

38. **(previously presented):** A composition comprising an isolated antibody or fragment thereof, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three complementarity-determining regions comprising the amino acid

**AMENDMENT UNDER 37 C.F.R. § 1.116**  
**U.S. Application No. 10/729,441 (A8689)**

sequences of SEQ ID NOS:1-3, and wherein said light chain variable region comprises three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:4-6, and wherein said antibody or said fragment specifically binds to IGF-IR; and

a therapeutic agent.

**39-40. (cancelled).**

**41. (currently amended):** A composition comprising an antibody or antibody fragment, wherein said antibody or said fragment specifically binds IGF-IR, and wherein said antibody comprises a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region comprises heavy chain complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:1-3, and wherein said light chain variable region comprises complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS: 4-6; and wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:8; and

a therapeutic agent.

**42. (currently amended):** A composition comprising an antibody or antibody fragment, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:1-3, and wherein said light chain variable region comprises three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:4-6,

respectively, and wherein said heavy chain variable region comprises SEQ ID NO:7; and wherein said antibody or said fragment specifically binds IGF-IR; and

a therapeutic agent.

**43. (cancelled).**

**44. (previously presented):** A composition comprising the antibody or fragment thereof of claim 38, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13.

**45. (currently amended):** A ~~pharmaceutical~~ composition comprising the antibody or antibody fragment of claim 38 and a pharmaceutically acceptable carrier.

**46. (previously presented):** A composition comprising a conjugate comprising the antibody or antibody fragment of claim 38 linked to a cytotoxic agent.

**47. (previously presented):** The composition of claim 46, wherein said cytotoxic agent is selected from the group consisting of a maytansinoid, a small drug, a prodrug, a taxoid, CC-1065 and a CC-1065 analog.

**48. (previously presented):** A pharmaceutical composition comprising the conjugate of claim 46 and a pharmaceutically acceptable carrier.



**AMENDMENT UNDER 37 C.F.R. § 1.116**  
**U.S. Application No. 10/729,441 (A8689)**

**49. (previously presented):** A composition comprising a diagnostic reagent comprising the composition of claim 45, wherein said antibody or antibody fragment is labeled with a detectable moiety.

**50. (previously presented):** The composition of claim 49, wherein said detectable moiety is selected from the group consisting of a radiolabel, a fluorophore, a chromophore, an imaging agent and a metal ion.

**51. (previously presented):** A method for inhibiting the growth of a cancer cell comprising contacting said cell with the composition of claim 38.

**52. (previously presented):** A method for treating a patient having a cancer comprising administering to said patient an effective amount of the composition of claim 38.

**53. (previously presented):** The method of claim 52 further comprising administering to said patient a therapeutic agent.

**54. (previously presented):** The method of claim 53, wherein said therapeutic agent is a cytotoxic agent.

**55. (previously presented):** A method for treating a patient having a cancer comprising administering to said patient an effective amount of the conjugate of claim 46.

**56. (previously presented):** The method of treatment of claim 52, wherein said cancer is a cancer selected from the group consisting of breast cancer, colon cancer, ovarian carcinoma, osteosarcoma, cervical cancer, prostate cancer, lung cancer, synovial carcinoma and pancreatic cancer.

**57. (withdrawn-previously presented):** A method for diagnosing a subject suspect of having a cancer, said method comprising:

administering to said subject the composition of claim 49; and

detecting the distribution of said reagent within said subject.

**58. (withdrawn-previously presented):** The method of diagnosis of claim 57, wherein said cancer is a cancer selected from the group consisting of breast cancer, colon cancer, ovarian carcinoma, osteosarcoma, cervical cancer, prostate cancer, lung cancer, synovial carcinoma and pancreatic cancer.

**59. (currently amended):** A composition comprising a murine antibody EM164 corresponding to ATCC(ATCC deposit number PTA-44574457) or a fragment thereof that specifically binds to an insulin-like growth factor-I receptor, wherein said antibody or fragment is an antagonist of said receptor and is devoid of agonist activity toward said receptor; and a therapeutic agent.

**60. (currently amended):** A composition comprising a humanized or resurfaced antibody EM164 corresponding to ATCC deposit number PTA-4457 or a fragment thereof that

**AMENDMENT UNDER 37 C.F.R. § 1.116**  
**U.S. Application No. 10/729,441 (A8689)**

specifically binds to an insulin-like growth factor-I receptor, wherein said antibody or fragment is an antagonist of said receptor and is devoid of agonist activity toward said receptor; and  
a therapeutic agent.

**61. (cancelled).**

**62. (currently amended):** The composition of claim 838, wherein the antibody or antibody fragment has at least one property selected from the group consisting of:

- a) inhibits cellular function of a IGF-IR without activating said IGF-IR; and
- b) inhibits tumor cell growth in the presence of serum by at least 80%.

**63. (currently amended):** The composition of claim 5562, wherein the antibody or antibody fragment has all of said properties.

**64-72. (cancelled).**